Use Of Enterofuril Suspension In The Treatment Of Diseases Associated With Helicobacteriosis


P.L. Shcherbakov, O.B. Janova, N.L. Belousova, A.A. Masharova, M.Yu. Shcherbakova, L.S. Goncharenko, L.D. Firsova, V.A. Kim, V.S. Kashnikov, V.M. Govorun

Central research Institute of gastroenterology of the Department of health of Moscow. The Institute of nutrition of RAMN, Moscow. Stavropol MMA, Stavropol. Institute of physico-chemical medicine, Moscow.
The issues of evolution of antihelicobacter therapy in recent years are considered. One of the problems in this area is the increasing resistance of Helicobacter pylori to metronidazole - a standard component of eradication therapy. In this regard, the Central Research Institute of Gastroenterology has been developed and tested a scheme of eradication therapy, including proton pump inhibitor, antibiotic clarithromycin, and Enterofuril® (nifuroxazide) as a third component. The article presents the results of study included 120 adult patients with H. pylori infection and various diseases of upper digestive tract treated with 7-day eradication therapy involving pantoprazole 20 mg twice a day, clarithromycin 500 mg 2 times a day, and Enterofuril or metronidazole as a third component. It was shown that the triple therapy of helicobacteriosis including suspension Enterofuril is very effective eradication scheme in adults, with superior to scheme with metronidazole efficacy and tolerability.

Similar Articles


Бионика Медиа